AstraZeneca Investing $300 Million into New Cutting-Edge Cell Therapy Facility in Maryland

Published on : Published by : Chris Frew

AstraZeneca Investing $300 Million into New Cutting-Edge Cell Therapy Facility in Maryland February 6, 2024 In a recent press release, Governor Wes Moore announced a groundbreaking initiative that positions Maryland [….]

Cartesian Therapeutics Announces Landmark Study in The Lancet Neurology of First Successful Clinical Trial of RNA Cell Therapy in Autoimmunity

Published on : Published by : Cat Thoreson

Cartesian Therapeutics, a clinical-stage biotechnology company pioneering cell therapies for autoimmune diseases, announced today the publication of a landmark paper in The Lancet Neurology. The study describes Descartes-08, a cutting-edge RNA CAR-T (rCAR-T) therapy administered to patients with generalized myasthenia gravis (MG), a debilitating autoimmune neurological disease. The data demonstrate marked and long-lasting clinical improvement in patients with MG. This is the first clinical trial using rCAR-T to treat autoimmunity, and the first successful Phase 2 trial using an engineered cell therapy to treat autoimmunity.

With Pandemic in Rearview Mirror, BriaCell Charges Ahead with Cancer Immunotherapy

Published on : Published by : Mark Terry

With Pandemic in Rearview Mirror, BriaCell Charges Ahead with Cancer Immunotherapy By Mark TerryApril 25, 2023 Many biopharma companies had to place their clinical trials on hold during the first [….]